supemtek
sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - chrípka, človek - vakcíny - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.
kesimpta
novartis ireland ltd - ofatumumab - roztrúsená skleróza, recidivujúce-odosielajúcej - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.
ponvory
janssen-cilag international n.v. - ponesimod - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.
fingolimod mylan
mylan ireland limited - fingolimod hydrochlorid - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 a 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
briumvi
neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresíva - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresíva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
dezmopresín stada 120 mikrogramov sublingválne tablety
stada arzneimittel ag, nemecko - dezmopresín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
dezmopresín stada 60 mikrogramov sublingválne tablety
stada arzneimittel ag, nemecko - dezmopresín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
dezmopresín stada 240 mikrogramov sublingválne tablety
stada arzneimittel ag, nemecko - dezmopresín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)